MCIA
ADMS

Mountain Capital Investment Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Mountain Capital Investment Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,400
Closed -$72K – 475
2017
Q3 		$72K Sell
3,400
-1,200
-26% -$22K 0.06% 88
2017
Q2 		$80K Buy
+4,600
New +$76.1K 0.08% 99

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Mountain Capital Investment Advisors's ADMS Position: Q4 2017 in Review

Mountain Capital Investment Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2017, closing a stake of 3,400 shares — an estimated $72K sold.

Mountain Capital Investment Advisors first reported a position in ADMS in Q2 2017 and held it in 2 quarters. The position peaked at $80K in Q2 2017. 117 funds tracked by Wall St. Rank hold ADMS as of Q4 2017.

  • Mountain Capital Investment Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Mountain Capital Investment Advisors sold 3,400 Adamas Pharmaceuticals shares in Q4 2017, an estimated $72K.
  • Mountain Capital Investment Advisors first reported a position in Adamas Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Mountain Capital Investment Advisors's Adamas Pharmaceuticals position peaked at $80K in Q2 2017.
  • 117 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2017.

Based on Mountain Capital Investment Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.